Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio

Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio

IntroductionBone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs) have dramatically changed the therapeutic landscape of NSCLC, little information is available on BMs from NSCLC treated with ICIs alone...

Full description

Bibliographic Details
Main Authors: Alberto Bongiovanni, Flavia Foca, Jessica Menis, Stefania Luigia Stucci, Fabrizio Artioli, Valentina Guadalupi, Maria Rosachiara Forcignanò, Manuela Fantini, Federica Recine, Laura Mercatali, Chiara Spadazzi, Marco Angelo Burgio, Valentina Fausti, Anna Miserocchi, Toni Ibrahim
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-11-01
Series:Frontiers in Immunology
Subjects:
immune checkpoint inhibitors
NSCLC
bone metastases
zoledronate
denosumab
lung cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.697298/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.697298/full

Similar Items